4.5 Article

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Endocrinology & Metabolism

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

Henry G. Bone et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)

Article Endocrinology & Metabolism

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Socrates Papapoulos et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2012)

Article Endocrinology & Metabolism

Bone Turnover Markers and Prediction of Fracture: A Prospective Follow-Up Study of 1040 Elderly Women for a Mean of 9 Years

Kaisa K. Ivaska et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2010)

Article Medicine, General & Internal

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Steven R. Cummings et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Article Pathology

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo

DL Lacey et al.

AMERICAN JOURNAL OF PATHOLOGY (2000)